These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12893398)

  • 21. Implementation of cardiovascular secondary prevention guidelines in clinical practice: a nationwide survey in Italy.
    Perrone-Filardi P; Poli A; Ambrosio G; Proto C; Chimini C; Chiariello M
    Nutr Metab Cardiovasc Dis; 2012 Feb; 22(2):149-53. PubMed ID: 20875948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid lowering therapy for adults with diabetes.
    Jackowski L; Crockett J; Rowett D
    Aust Fam Physician; 2008; 37(1-2):39-41. PubMed ID: 18239751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
    Dupuy AM; Carrière I; Scali J; Cristol JP; Ritchie K; Dartigues JF; Gambert P; Ancelin ML
    Climacteric; 2008 Feb; 11(1):74-83. PubMed ID: 18202967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of new cholesterol guidelines to a population-based sample.
    Pencina MJ; Navar-Boggan AM; D'Agostino RB; Williams K; Neely B; Sniderman AD; Peterson ED
    N Engl J Med; 2014 Apr; 370(15):1422-31. PubMed ID: 24645848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of improved lipid control in patients at high risk for adverse cardiac events.
    Jena AB; Blumenthal DM; Stevens W; Chou JW; Ton TG; Goldman DP
    Am J Manag Care; 2016 Jun; 22(6):e199-207. PubMed ID: 27355907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secular trends in cardiovascular disease risk factors according to body mass index in US adults.
    Gregg EW; Cheng YJ; Cadwell BL; Imperatore G; Williams DE; Flegal KM; Narayan KM; Williamson DF
    JAMA; 2005 Apr; 293(15):1868-74. PubMed ID: 15840861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in cardiovascular risk factors among U.S. men and women with and without diabetes, 1988-2014.
    Sun X; Du T
    BMC Public Health; 2017 Nov; 17(1):893. PubMed ID: 29166886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.
    Yang Q; Zhong Y; Gillespie C; Merritt R; Bowman B; George MG; Flanders WD
    BMJ Open; 2017 Jan; 7(1):e011684. PubMed ID: 28119384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
    Gouni-Berthold I; Krone W
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-lowering treatment for all could substantially reduce the burden of macrovascular complications of diabetes patients in the Netherlands.
    Jacobs-van der Bruggen MA; Engelfriet PM; Hoogenveen RT; van Baal PH; Struijs JN; Verschuren WM; Smit HA; Baan CA
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):521-5. PubMed ID: 18830084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes.
    Hero C; Rawshani A; Svensson AM; Franzén S; Eliasson B; Eeg-Olofsson K; Gudbjörnsdottir S
    Diabetes Care; 2016 Jun; 39(6):996-1003. PubMed ID: 27208327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany.
    Gitt AK; Sonntag F; Jannowitz C; Weizel A; Karmann B; Schaefer JR; Pittrow D; Hildemann SK
    Curr Med Res Opin; 2016; 32(3):417-26. PubMed ID: 26568400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
    Grover SA; Coupal L; Gilmore N; Mukherjee J
    Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does use of pooled cohort risk score overestimate the use of statin?: a retrospective cohort study in a primary care setting.
    Chia YC; Lim HM; Ching SM
    BMC Fam Pract; 2014 Nov; 15():172. PubMed ID: 25388219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease.
    Johnson ML; Pietz K; Battleman DS; Beyth RJ
    Am J Manag Care; 2004 Dec; 10(12):926-32. PubMed ID: 15617368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.